Natco Pharma has received a favorable ruling as the Commercial Appellate Division of the Delhi High Court dismissed an appeal regarding Risdiplam. This clears the path for Natco to launch its generic version of the drug used to treat Spinal Muscular Atrophy (SMA) in India. The company plans to launch the product immediately, priced at INR 15,900, with potential discounts for eligible patients.
Favorable Court Ruling
The Commercial Appellate Division of the Hon’ble Delhi High Court has dismissed an appeal, paving the way for Natco Pharma to launch its generic version of Risdiplam in India. The original order denying an injunction against Natco was dated March 24, 2025. This recent dismissal effectively removes the final hurdle for the company.
Risdiplam and SMA Treatment
Risdiplam is a medication used in the treatment of Spinal Muscular Atrophy (SMA), a debilitating disease. With the court’s decision, Natco Pharma can now provide a more affordable treatment option to Indian patients. The company highlights the lack of curative options and the financial challenges faced by Indian patients when accessing available treatments.
Launch and Pricing Details
Natco Pharma intends to launch Risdiplam immediately, pricing it at INR 15,900 per unit. The company is also considering offering discounts to certain patients in need through a dedicated patient access program. This initiative aims to make the treatment more accessible.
About Natco Pharma
Natco Pharma is an Indian pharmaceutical company specializing in the development, manufacture, and distribution of generic and branded drugs, specialty pharmaceuticals, active pharmaceutical ingredients, and crop protection products. They maintain 9 manufacturing sites and 2 R&D facilities within India. They cater to 50+ global markets.
Source: BSE
